CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 46 enrolled
Drug / intervention
pixantrone dimaleatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01086605
NCT01086605Phase 2Completed
CompareCT.gov

Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer

Alliance for Clinical Trials in Oncology·interventional·Posted Mar 15, 2010·Updated May 8, 2018

In Brief

A Phase 2 clinical trial evaluating pixantrone dimaleate for Breast Cancer. Completed, enrolled 46 participants across 230 sites.

Detailed Summary

RATIONALE: Drugs used in chemotherapy, such as pixantrone dimaleate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving pixantrone dimaleate in different ways may kill more tumor cells. PURPOSE: This randomized phase II trial is studying how well pixantrone dimaleate works in treating patients with HER2-negative metastatic breast cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 15, 2010
Enrollment StartMay 1, 2010
Primary CompletionJan 1, 2012
Study CompletionNov 15, 2014
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 16.3 years ago

Interventions

pixantrone dimaleatedrug

Given IV